Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00334152 · ClinicalTrials.gov registry record · Phase 3

Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women

A Phase 3 study of Postoperative Nausea and Vomiting and Nausea and Vomiting, Postoperative, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 3
Development phase
515
Enrollment target
20
Study locations

NCT00334152 is a Phase 3 study of Postoperative Nausea and Vomiting and Nausea and Vomiting, Postoperative that has completed, run by GlaxoSmithKline. The registered enrollment target is 515 participants, above the 414-participant average among 9 other Postoperative Nausea and Vomiting trials with a reported enrollment target (24% higher). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00334152, a Phase 3 study of Postoperative Nausea and Vomiting and Nausea and Vomiting, Postoperative, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 3
Development phase
515 participants
Enrollment target
20
Study locations

Study Summary

This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.

Conditions Studied

Postoperative Nausea and Vomiting Nausea and Vomiting, Postoperative

Interventions

  • DRUG casopitant

Study Locations (20)

California

  • GSK Investigational Site - Arcadia
  • GSK Investigational Site - Glendale
  • GSK Investigational Site - Laguna Hills
  • GSK Investigational Site - Pasadena

Florida

  • GSK Investigational Site - Boca Raton
  • GSK Investigational Site - Melbourne
  • GSK Investigational Site - Miami
  • GSK Investigational Site - West Palm Beach

Alabama

  • GSK Investigational Site - Fairhope
  • GSK Investigational Site - Mobile
  • GSK Investigational Site - Montgomery

New York

  • GSK Investigational Site - Mineola
  • GSK Investigational Site - New Hyde Park
  • GSK Investigational Site - New York

Arkansas

  • GSK Investigational Site - Little Rock

Illinois

  • GSK Investigational Site - Chicago

Kansas

  • GSK Investigational Site - Kansas City

Maryland

  • GSK Investigational Site - Baltimore

Trial Details

FieldValue
Enrollment Target 515 participants
Start Date 2006-03
Est. Completion 2006-07
Phase Phase 3

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00334152

The ClinicalTrials.gov registry entry for NCT00334152 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 515 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 414-participant average among 9 other Postoperative Nausea and Vomiting trials with a reported enrollment target (24% higher). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Postoperative Nausea and Vomiting appearing as the primary indexed condition, and to 1 intervention - of which casopitant is the first listed.

NCT00334152 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Alabama.

Frequently Asked Questions

What is clinical trial NCT00334152 about?

NCT00334152 is a clinical study titled "Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women". This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.

What is the current status of trial NCT00334152?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 515 participants. The study started on 2006-03. Estimated completion is 2006-07.

What conditions does trial NCT00334152 study?

This clinical trial studies the following conditions: Postoperative Nausea and Vomiting, Nausea and Vomiting, Postoperative.

What interventions are being tested in trial NCT00334152?

The interventions under investigation include: casopitant (DRUG).

Who is sponsoring clinical trial NCT00334152?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00334152 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Postoperative Nausea and Vomiting

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Postoperative Nausea and Vomiting

All registered trials for this condition

Nausea and Vomiting, Postoperative

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.